Kingma P J, Simons J P, Nieuwenhuijzen Kruseman A C, Wolffenbuttel B H
Department of Internal Medicine, University Hospital Maastricht.
Neth J Med. 1990 Feb;36(1-2):32-8.
Calcium entry blockers have been used for cardiovascular disturbances such as angina pectoris and hypertension. Calcium is, however, involved in the release of several hormones. The process of insulin secretion by the pancreatic beta-cells is dependent on calcium. Thus, calcium-entry blockers may interfere with insulin secretion. This effect has been confirmed in vitro in isolated islets as well as in animal studies. A few case reports describe the deterioration of glycaemic control or development of frank diabetes mellitus during treatment with nifedipine or diltiazem. In general, however, there are no important negative effects of calcium-entry blockers on glucose tolerance, either in non-diabetic persons with hypertension, or in patients with diabetes mellitus. Hence, these drugs appear to be a good choice for use in diabetic patients with cardiovascular diseases.
钙通道阻滞剂已被用于治疗心血管疾病,如心绞痛和高血压。然而,钙参与多种激素的释放。胰腺β细胞分泌胰岛素的过程依赖于钙。因此,钙通道阻滞剂可能会干扰胰岛素分泌。这种作用已在体外分离的胰岛以及动物研究中得到证实。一些病例报告描述了在使用硝苯地平或地尔硫䓬治疗期间血糖控制恶化或出现明显的糖尿病。然而,总体而言,钙通道阻滞剂对糖耐量没有重要的负面影响,无论是在患有高血压的非糖尿病患者中,还是在糖尿病患者中。因此,这些药物似乎是患有心血管疾病的糖尿病患者的良好选择。